T1	Participants 180 408	283 patients with active duodenal ulcer to compare possible factors that may affect healing and relapse in patients treated with a potent antisecretory agent, cimetidine, or a site-protective and cytoprotective agent, sucralfate
T2	Participants 1170 1242	patients with healed ulcers, 238 participated in a 24-mo follow-up study
